Literature DB >> 6814005

Measurement of human factor IXa activity in an isolated factor X activation system.

M J Griffith, H M Reisner, R L Lundblad, H R Roberts.   

Abstract

To determine the functional properties of factor IX isolated from the plasma of CRM+ hemophilia B patients, an assay system using proteins isolated from human plasma had to be developed which would be amenable to kinetic studies under a variety of experimental conditions. The present study describes the activation of factor X by factor IXa, isolated from normal human plasma, in an assay system which allows manipulation of calcium, phospholipid and factor VIIIa concentrations. Initial rate measurements with factor VIIIa present in the system were made by incubating factor VIII with factor Xa immediately before factor IXa assay. With this approach, the initial rate of factor X activation was constant, with little evidence for a lag period. Within the framework of the assay system described in the present study, it should be possible to examine not only genetic variants of factor IX, but also variants of factor VIII, as well as providing a means of routine factor IXa and factor VIII(a) assays.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814005     DOI: 10.1016/0049-3848(82)90076-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Internal duplication and sequence homology in factors V and VIII.

Authors:  D N Fass; R M Hewick; G J Knutson; M E Nesheim; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 3.  Phosphatidylserine Regulation of Coagulation Proteins Factor IXa and Factor VIIIa.

Authors:  Rinku Majumder
Journal:  J Membr Biol       Date:  2022-09-13       Impact factor: 2.426

4.  Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.

Authors:  M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

5.  Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.

Authors:  M J Griffith; L Breitkreutz; H Trapp; E Briet; C M Noyes; R L Lundblad; H R Roberts
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

6.  The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX.

Authors:  K Mertens; R M Bertina
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

7.  Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.

Authors:  Dougald M Monroe; Richard J Jenny; Kevin E Van Cott; Shelly Buhay; Laura L Saward
Journal:  Adv Hematol       Date:  2016-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.